Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

I. Jialal, D. Stein, David S Balis, Scott M Grundy, Beverley A Huet, S. Devaraj

Research output: Contribution to journalArticle

659 Citations (Scopus)

Abstract

Background - Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients. Thus, we tested the effects of 3 hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), simvastatin (20 mg/d), pravastatin (40 mg/d), and atorvastatin (10 mg/d), on levels of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipidemia (LDL cholesterol > 130 mg/dL and triglycerides of 200 to 600 mg/dL). Methods and Results - After 6 weeks of an American Heart Association Step 1 diet, fasting blood samples were drawn at baseline and after 6 weeks of therapy with each drug. hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). The reductions obtained with the 3 statins were similar. In addition, there was no significant effect on either plasma interleukin-6 or interleukin-6 soluble receptor levels. There was no relationship between reductions in hs-CRP and LDL cholesterol. Conclusions - Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. These data support an anti-inflammatory effect of these drugs.

Original languageEnglish (US)
Pages (from-to)1933-1935
Number of pages3
JournalCirculation
Volume103
Issue number15
StatePublished - Apr 17 2001

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pravastatin
Simvastatin
Coenzymes
C-Reactive Protein
Oxidoreductases
LDL Cholesterol
Interleukin-6 Receptors
Hyperlipidemias
Pharmaceutical Preparations
Cross-Over Studies
Interleukin-6
Fasting
Triglycerides
Anti-Inflammatory Agents
Therapeutics
Prospective Studies
Diet
Inflammation
Atorvastatin Calcium

Keywords

  • C-reactive protein
  • Inflammation
  • Statins

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. / Jialal, I.; Stein, D.; Balis, David S; Grundy, Scott M; Huet, Beverley A; Devaraj, S.

In: Circulation, Vol. 103, No. 15, 17.04.2001, p. 1933-1935.

Research output: Contribution to journalArticle

@article{a7292b86332b40e78aaabe0a61482a56,
title = "Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels",
abstract = "Background - Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients. Thus, we tested the effects of 3 hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), simvastatin (20 mg/d), pravastatin (40 mg/d), and atorvastatin (10 mg/d), on levels of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipidemia (LDL cholesterol > 130 mg/dL and triglycerides of 200 to 600 mg/dL). Methods and Results - After 6 weeks of an American Heart Association Step 1 diet, fasting blood samples were drawn at baseline and after 6 weeks of therapy with each drug. hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). The reductions obtained with the 3 statins were similar. In addition, there was no significant effect on either plasma interleukin-6 or interleukin-6 soluble receptor levels. There was no relationship between reductions in hs-CRP and LDL cholesterol. Conclusions - Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. These data support an anti-inflammatory effect of these drugs.",
keywords = "C-reactive protein, Inflammation, Statins",
author = "I. Jialal and D. Stein and Balis, {David S} and Grundy, {Scott M} and Huet, {Beverley A} and S. Devaraj",
year = "2001",
month = "4",
day = "17",
language = "English (US)",
volume = "103",
pages = "1933--1935",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

AU - Jialal, I.

AU - Stein, D.

AU - Balis, David S

AU - Grundy, Scott M

AU - Huet, Beverley A

AU - Devaraj, S.

PY - 2001/4/17

Y1 - 2001/4/17

N2 - Background - Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients. Thus, we tested the effects of 3 hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), simvastatin (20 mg/d), pravastatin (40 mg/d), and atorvastatin (10 mg/d), on levels of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipidemia (LDL cholesterol > 130 mg/dL and triglycerides of 200 to 600 mg/dL). Methods and Results - After 6 weeks of an American Heart Association Step 1 diet, fasting blood samples were drawn at baseline and after 6 weeks of therapy with each drug. hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). The reductions obtained with the 3 statins were similar. In addition, there was no significant effect on either plasma interleukin-6 or interleukin-6 soluble receptor levels. There was no relationship between reductions in hs-CRP and LDL cholesterol. Conclusions - Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. These data support an anti-inflammatory effect of these drugs.

AB - Background - Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients. Thus, we tested the effects of 3 hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), simvastatin (20 mg/d), pravastatin (40 mg/d), and atorvastatin (10 mg/d), on levels of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipidemia (LDL cholesterol > 130 mg/dL and triglycerides of 200 to 600 mg/dL). Methods and Results - After 6 weeks of an American Heart Association Step 1 diet, fasting blood samples were drawn at baseline and after 6 weeks of therapy with each drug. hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). The reductions obtained with the 3 statins were similar. In addition, there was no significant effect on either plasma interleukin-6 or interleukin-6 soluble receptor levels. There was no relationship between reductions in hs-CRP and LDL cholesterol. Conclusions - Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. These data support an anti-inflammatory effect of these drugs.

KW - C-reactive protein

KW - Inflammation

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0035901619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035901619&partnerID=8YFLogxK

M3 - Article

C2 - 11306519

AN - SCOPUS:0035901619

VL - 103

SP - 1933

EP - 1935

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 15

ER -